View ValuationItem 9 Labs 将来の成長Future 基準チェック /06現在、 Item 9 Labsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 25Item 9 Labs Corp. Declines Re-Election of Lisa Rejler as Board MemberItem 9 Labs Corp. announced that the Nomination Committee proposes that the Annual General Meeting shall re-elect the board members Peter Rejler, Jan Samuelsson, Patrik Boman, Peter Johansson and Susanne Blanke and that the General Meeting resolves on new election of Martina Rejler. The board member Lisa Rejler declines re-election, at the AGM to be held on April 24, 2025.お知らせ • Apr 11Item 9 Labs Corp., Annual General Meeting, May 16, 2024Item 9 Labs Corp., Annual General Meeting, May 16, 2024, at 14:00 Central European Standard Time. Location: Östra Hamngatan 52 Gothenburg Sweden Agenda: To consider Presentation of the annual financial report and the auditor's report, as well as the consolidated annual financial report, the consolidated auditor's report and the Board of Directors' report; to consider (a) the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet as well as the Board of Directors report pursuant to Chapter 8, Section 53a of the Swedish Companies Act, (b) the disposition of the Company's funds according to the adopted balance sheet and (c) the discharge from liability for the members of the Board of Directors and the CEO; to consider the election of members of the Board of Directors and appointment of auditors and deputy auditors, if any; and to consider any other matters.お知らせ • Jul 23+ 1 more updateDouglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023Douglas Bowden has resigned his positions as Chairman of the Board of Directors of Item 9 Labs Corp, effective July 18, 2023. The positions will be left vacant until further notice due to the receivership appointment.お知らせ • May 25Item 9 Labs Corp. Announces Management ChangesItem 9 Labs Corp. announced that Director Jeffrey Rassás has been appointed to Strategic Advisor and will be primarily driving investor & public relations as well as capital needs. Chris Wolven, current Chief Operating Officer, will now oversee all Company entities and operations and will be the primary Company-facing executive for Item 9 Labs Corp. Michael Keskey has resigned as Chief Legal Officer.お知らせ • May 23+ 1 more updateItem 9 Labs Corp. Announces CEO ChangesItem 9 Labs Corp. announced that on May 17, 2023, Mr. Michael Weinberger voluntarily resigned as Chief Executive Officer and member of the Board of Directors of the Company. On May 22, 2023, the Board appointed Mr. Douglas Bowden, age 63, as the Company’s Interim Chief Executive Officer. Mr. Bowden is currently the Chairman of the Company’s Board of Directors. The biography for Mr. Bowden is set forth below: Mr. Bowden started his career in the electronics industry, working in a successful family run business, which he purchased with his brother and ran for nearly 20 years. This tech company's success was based on signal processing and monitoring providing hardware and software for broadcasters during the high definition revolution. Bowden sold his business in 2009 and in 2013, Mr. Bowden and his son started Viridis Group, a real estate company centered on residential remodeling, multifamily and commercial real estate development in Colorado and Arizona. Through this venture they gained experience in real estate acquisition, design, project and construction management, leasing, finance and sales. Viridis Group has recently adopted the name Bowden Investment Group. Mr. Bowden attended the University of South Dakota where he studied business. Mr. Bowden is co-founder of Viridis Group, dba Bowden Investment Group, a strategic partner of the Company.お知らせ • May 16Item 9 Labs Corp. announced delayed 10-Q filingOn 05/15/2023, Item 9 Labs Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 11Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-RollsItem 9 Labs announced the latest release of its limited edition one-gram rosin-infused pre-rolls in participating Arizona dispensaries. The product release follows a successful initial test run in December 2022 that immediately sold out after being stocked in local dispensaries and generated extremely positive customer and budtender feedback on the product quality. The demand for solventless cannabis products in Arizona has continued to grow since the start of the state's adult-use cannabis market, especially in the concentrate and vape categories. The niche sector provides a consistent, high quality and fuller expression of the various cannabinoids and terpenes that the cannabis plant has to offer. Cannabis data firm BDSA analyzed product data from the past year and noted that the growing rosin category is making a significant mark among many mature markets in the evolving industry, counting single to double-digit growth in sales from 2021 to 2022. Item 9 Labs' addition of rosin-infused pre therolls bolsters its already extensive product lineup of connoisseur grade pre-rolls, featuring one-gram pre-rolls crafted with its award-winning flower and infused with live resin sugar, live resin badder or crumble concentrates. According to BDSA's most recent market research, Item 9 Labs ranked No. 3 in Arizona's one-gram infused pre-roll category for February 2023, capturing 8.5% market share. Overall, the state generated $4.16 million in infused pre-rolls that month. Being sold in over 65% of Arizona's dispensaries, Item 9 Labs is recognized as one of the top 10 leading cannabis brands in the state. The rosin-infused pre -infused pre-rolls are sold at participating Botanica, JARS and Nature's Medicines locations, among other dispensaries throughout Phoenix.お知らせ • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2022, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 09Item 9 Labs Corp. Announces Management PromotionsItem 9 Labs Corp. announced promotion of Mark Busch, Senior Vice President of Corporate Development, Cory Carter, Senior Vice President of Cultivation and Jayne Levy Senior Vice President of Communications. Mark Busch is One of the first hires on the Unity Rd. brand, Busch joined in 2018, pre-dating Item 9 Labs Corp.'s acquisition of Unity Rd.'s franchisor, OCG Inc. in 2021. He is responsible for overseeing merger and acquisition strategy and activities. He has led the team through acquisitions of multiple dispensaries and most recently, has been spearheading the Company's approaching acquisition of Sessions. Carter joined OCG Inc. in 2019 and took over all Item 9 Labs Corp. cultivation operations upon acquisition close. He is lead on all production, manufacturing and packaging of the Company's award-winning Item 9 Labs cannabis products, including managing a team of 50-plus and aiding in the continued development of the Company's cultivation and lab site in Coolidge, Ariz. Levy has been with Unity Rd. since the cannabis franchise's inception in 2018. She plays an integral role in the Company with a hand in all facets of communications – spearheading internal and corporate communications, investor relations, public relations and beyond.お知らせ • Dec 01+ 1 more updateItem 9 Labs Corp. Announces Resignation of Andrew Bowden as DirectorOn November 23, 2022, Mr. Andrew Bowden voluntarily resigned as Chief Executive Officer and member of the Board of Directors of Item 9 Labs Corp. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company is appreciative of Mr. Bowden’s years of service to the Company as a director and Chief Executive Officer.お知らせ • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022お知らせ • Jun 05Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy OfficerOn June 1, 2022, Mr. Jeffrey Rassas resigned, effective immediately, as the Chief Strategy Officer of Item 9 Labs Corp. (the Company") and the Company's management accepted Mr. Rassas' resignation on June 1, 2022. Mr. Rassas' resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, practices, or otherwise. Mr. Rassas will remain on the Company's board of directors and will continue working with the Company in a consulting role.お知らせ • May 26Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million on May 18, 2022. As per the terms of the transaction, Item 9 Labs shall pay $12.8 million plus the earnout payments of $4.1 million of common stock 12 months following the closing date and $4.1 million common stock 24 months following the closing date subject to post-closing adjustments. Item 9 Labs Corp. shall pay a termination fee of $0.54 million to the sellers. The transaction is subject to customary closing conditions including Item 9 Labs receiving financing sufficient to complete the transaction and Sessions Cannabis shall have a minimum cash balance of $0.1 million. Frank Robinson and Jeffrey Mikelberg of Cassels Brock & Blackwell LLP acted as legal advisors to the sellers and Francesco Gucciardo and Gary Volman of Aird & Berlis LLP acted as legal advisor to Item 9 Labs Corp.お知らせ • Mar 06Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC.Item 9 Labs Corp. (OTCPK:INLB) agreed to acquire Certain Assets of Nebrina Adams County LLC for $2 million on October 6, 2021. The total purchase price will be payable as follows: (i) Upon conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars. ii) At the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following the Closing Date (the " Note " or " Promissory Note" ) until paid in full; and (iii) Buyer shall issue to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject to a leak out agreement. Closing shall be contingent upon the unconditional approval by MED and the Local Licensing Authority of the Transactions. Jean Gonnell of Gonnell Law acted as legal advisor to Nebrina. Zuber Lawler & Del Duca LLP acted as legal advisor to Item 9. Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC on March 4, 2022.お知らせ • Mar 04Item 9 Labs Corp. Appoints Shane Evans to Its Board of DirectorsItem 9 Labs Corp. announced that Shane Evans, founder of Massage Heights, has been appointed to its Board of Directors.お知らせ • Feb 03Item 9 Labs Corp. Announces Resignation of Ronald L. Miller, Jr. from the Board of DirectorsOn January 25, 2022, Mr. Ronald L. Miller, Jr. resigned, effective immediately, from the board of directors of Item 9 Labs Corp. and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role.お知らせ • Dec 31Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/30/2021, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2020, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 26Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million.Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million on February 27, 2020. Under the terms of the transaction, Item 9 Labs Corp. will issue 30 million restricted shares as consideration to acquire 52.22 million shares of OCG Inc. resulting in an exchange ratio of 0.575 shares of Item 9 Labs Corp. for each share of OCG Inc. Upon closing, OCG Inc. will become a wholly-owned direct subsidiary of Item 9 Labs Corp. Upon closing of the transaction, OCG Inc. may nominate, and Item 9 Labs Corp. agrees to appoint, two persons designated by OCG Inc. to Item 9 Labs Corp.’s Board of Directors. The transaction is subject to the adoption of the agreement by the requisite vote of the stockholders of OCG Inc. and Item 9 Labs Corp., approval of the issuance of shares of Item 9 Labs Corp. as merger consideration, an appropriate level and Director and Officers Liability Insurance being in place, financing contingency that Item 9 Labs Corp. must raise approximately $2 million and delivery by OCG Inc. of copies of a lock up and leak out agreement. The Board of Directors of Item 9 Labs Corp. has approved the agreement and the transactions contemplated hereby. The transaction is expected to closing in early July 2020. The transaction is expected to close near the Item 9 Labs’s fiscal year end of September 30, 2020. Michael Weiner and David Mangum of Dorsey & Whitney LLP acted as legal advisors for OCG, Inc. Jessica M. Lockett of Horwitz +Armstrong acted as legal advisor for Item 9 Labs Corp. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Item 9 Labs は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:INLB - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202320-31-3-1N/A3/31/202320-31-5-4N/A12/31/202221-31-6-3N/A9/30/202222-31-8-2N/A6/30/202224-22-5-1N/A3/31/202226-17-7-1N/A12/31/202125-13-9-4N/A9/30/202122-11-8-6N/A6/30/202118-9-9-7N/A3/31/202114-10-6-5N/A12/31/202010-11-3-3N/A9/30/20208-12-1-1N/A6/30/20207-13-4-2N/A3/31/20206-12-7-1N/A12/31/20196-11-8-2N/A9/30/20195-10-8-2N/A6/30/20194-2-7-2N/A3/31/20193-2-3-3N/A12/31/20182-1-2-2N/A9/30/20181-1-1-1N/A9/30/20170000N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: INLBの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: INLBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: INLBの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: INLBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: INLBの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: INLBの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 16:34終値2026/05/11 00:00収益2023/06/30年間収益2022/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Item 9 Labs Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Joseph GomesNOBLE Capital Markets, Inc.
お知らせ • Mar 25Item 9 Labs Corp. Declines Re-Election of Lisa Rejler as Board MemberItem 9 Labs Corp. announced that the Nomination Committee proposes that the Annual General Meeting shall re-elect the board members Peter Rejler, Jan Samuelsson, Patrik Boman, Peter Johansson and Susanne Blanke and that the General Meeting resolves on new election of Martina Rejler. The board member Lisa Rejler declines re-election, at the AGM to be held on April 24, 2025.
お知らせ • Apr 11Item 9 Labs Corp., Annual General Meeting, May 16, 2024Item 9 Labs Corp., Annual General Meeting, May 16, 2024, at 14:00 Central European Standard Time. Location: Östra Hamngatan 52 Gothenburg Sweden Agenda: To consider Presentation of the annual financial report and the auditor's report, as well as the consolidated annual financial report, the consolidated auditor's report and the Board of Directors' report; to consider (a) the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet as well as the Board of Directors report pursuant to Chapter 8, Section 53a of the Swedish Companies Act, (b) the disposition of the Company's funds according to the adopted balance sheet and (c) the discharge from liability for the members of the Board of Directors and the CEO; to consider the election of members of the Board of Directors and appointment of auditors and deputy auditors, if any; and to consider any other matters.
お知らせ • Jul 23+ 1 more updateDouglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023Douglas Bowden has resigned his positions as Chairman of the Board of Directors of Item 9 Labs Corp, effective July 18, 2023. The positions will be left vacant until further notice due to the receivership appointment.
お知らせ • May 25Item 9 Labs Corp. Announces Management ChangesItem 9 Labs Corp. announced that Director Jeffrey Rassás has been appointed to Strategic Advisor and will be primarily driving investor & public relations as well as capital needs. Chris Wolven, current Chief Operating Officer, will now oversee all Company entities and operations and will be the primary Company-facing executive for Item 9 Labs Corp. Michael Keskey has resigned as Chief Legal Officer.
お知らせ • May 23+ 1 more updateItem 9 Labs Corp. Announces CEO ChangesItem 9 Labs Corp. announced that on May 17, 2023, Mr. Michael Weinberger voluntarily resigned as Chief Executive Officer and member of the Board of Directors of the Company. On May 22, 2023, the Board appointed Mr. Douglas Bowden, age 63, as the Company’s Interim Chief Executive Officer. Mr. Bowden is currently the Chairman of the Company’s Board of Directors. The biography for Mr. Bowden is set forth below: Mr. Bowden started his career in the electronics industry, working in a successful family run business, which he purchased with his brother and ran for nearly 20 years. This tech company's success was based on signal processing and monitoring providing hardware and software for broadcasters during the high definition revolution. Bowden sold his business in 2009 and in 2013, Mr. Bowden and his son started Viridis Group, a real estate company centered on residential remodeling, multifamily and commercial real estate development in Colorado and Arizona. Through this venture they gained experience in real estate acquisition, design, project and construction management, leasing, finance and sales. Viridis Group has recently adopted the name Bowden Investment Group. Mr. Bowden attended the University of South Dakota where he studied business. Mr. Bowden is co-founder of Viridis Group, dba Bowden Investment Group, a strategic partner of the Company.
お知らせ • May 16Item 9 Labs Corp. announced delayed 10-Q filingOn 05/15/2023, Item 9 Labs Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 11Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-RollsItem 9 Labs announced the latest release of its limited edition one-gram rosin-infused pre-rolls in participating Arizona dispensaries. The product release follows a successful initial test run in December 2022 that immediately sold out after being stocked in local dispensaries and generated extremely positive customer and budtender feedback on the product quality. The demand for solventless cannabis products in Arizona has continued to grow since the start of the state's adult-use cannabis market, especially in the concentrate and vape categories. The niche sector provides a consistent, high quality and fuller expression of the various cannabinoids and terpenes that the cannabis plant has to offer. Cannabis data firm BDSA analyzed product data from the past year and noted that the growing rosin category is making a significant mark among many mature markets in the evolving industry, counting single to double-digit growth in sales from 2021 to 2022. Item 9 Labs' addition of rosin-infused pre therolls bolsters its already extensive product lineup of connoisseur grade pre-rolls, featuring one-gram pre-rolls crafted with its award-winning flower and infused with live resin sugar, live resin badder or crumble concentrates. According to BDSA's most recent market research, Item 9 Labs ranked No. 3 in Arizona's one-gram infused pre-roll category for February 2023, capturing 8.5% market share. Overall, the state generated $4.16 million in infused pre-rolls that month. Being sold in over 65% of Arizona's dispensaries, Item 9 Labs is recognized as one of the top 10 leading cannabis brands in the state. The rosin-infused pre -infused pre-rolls are sold at participating Botanica, JARS and Nature's Medicines locations, among other dispensaries throughout Phoenix.
お知らせ • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2022, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 09Item 9 Labs Corp. Announces Management PromotionsItem 9 Labs Corp. announced promotion of Mark Busch, Senior Vice President of Corporate Development, Cory Carter, Senior Vice President of Cultivation and Jayne Levy Senior Vice President of Communications. Mark Busch is One of the first hires on the Unity Rd. brand, Busch joined in 2018, pre-dating Item 9 Labs Corp.'s acquisition of Unity Rd.'s franchisor, OCG Inc. in 2021. He is responsible for overseeing merger and acquisition strategy and activities. He has led the team through acquisitions of multiple dispensaries and most recently, has been spearheading the Company's approaching acquisition of Sessions. Carter joined OCG Inc. in 2019 and took over all Item 9 Labs Corp. cultivation operations upon acquisition close. He is lead on all production, manufacturing and packaging of the Company's award-winning Item 9 Labs cannabis products, including managing a team of 50-plus and aiding in the continued development of the Company's cultivation and lab site in Coolidge, Ariz. Levy has been with Unity Rd. since the cannabis franchise's inception in 2018. She plays an integral role in the Company with a hand in all facets of communications – spearheading internal and corporate communications, investor relations, public relations and beyond.
お知らせ • Dec 01+ 1 more updateItem 9 Labs Corp. Announces Resignation of Andrew Bowden as DirectorOn November 23, 2022, Mr. Andrew Bowden voluntarily resigned as Chief Executive Officer and member of the Board of Directors of Item 9 Labs Corp. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company is appreciative of Mr. Bowden’s years of service to the Company as a director and Chief Executive Officer.
お知らせ • Aug 04Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022
お知らせ • Jun 05Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy OfficerOn June 1, 2022, Mr. Jeffrey Rassas resigned, effective immediately, as the Chief Strategy Officer of Item 9 Labs Corp. (the Company") and the Company's management accepted Mr. Rassas' resignation on June 1, 2022. Mr. Rassas' resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, practices, or otherwise. Mr. Rassas will remain on the Company's board of directors and will continue working with the Company in a consulting role.
お知らせ • May 26Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million on May 18, 2022. As per the terms of the transaction, Item 9 Labs shall pay $12.8 million plus the earnout payments of $4.1 million of common stock 12 months following the closing date and $4.1 million common stock 24 months following the closing date subject to post-closing adjustments. Item 9 Labs Corp. shall pay a termination fee of $0.54 million to the sellers. The transaction is subject to customary closing conditions including Item 9 Labs receiving financing sufficient to complete the transaction and Sessions Cannabis shall have a minimum cash balance of $0.1 million. Frank Robinson and Jeffrey Mikelberg of Cassels Brock & Blackwell LLP acted as legal advisors to the sellers and Francesco Gucciardo and Gary Volman of Aird & Berlis LLP acted as legal advisor to Item 9 Labs Corp.
お知らせ • Mar 06Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC.Item 9 Labs Corp. (OTCPK:INLB) agreed to acquire Certain Assets of Nebrina Adams County LLC for $2 million on October 6, 2021. The total purchase price will be payable as follows: (i) Upon conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars. ii) At the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following the Closing Date (the " Note " or " Promissory Note" ) until paid in full; and (iii) Buyer shall issue to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject to a leak out agreement. Closing shall be contingent upon the unconditional approval by MED and the Local Licensing Authority of the Transactions. Jean Gonnell of Gonnell Law acted as legal advisor to Nebrina. Zuber Lawler & Del Duca LLP acted as legal advisor to Item 9. Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC on March 4, 2022.
お知らせ • Mar 04Item 9 Labs Corp. Appoints Shane Evans to Its Board of DirectorsItem 9 Labs Corp. announced that Shane Evans, founder of Massage Heights, has been appointed to its Board of Directors.
お知らせ • Feb 03Item 9 Labs Corp. Announces Resignation of Ronald L. Miller, Jr. from the Board of DirectorsOn January 25, 2022, Mr. Ronald L. Miller, Jr. resigned, effective immediately, from the board of directors of Item 9 Labs Corp. and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role.
お知らせ • Dec 31Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/30/2021, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 30Item 9 Labs Corp. announced delayed annual 10-K filingOn 12/29/2020, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 26Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million.Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million on February 27, 2020. Under the terms of the transaction, Item 9 Labs Corp. will issue 30 million restricted shares as consideration to acquire 52.22 million shares of OCG Inc. resulting in an exchange ratio of 0.575 shares of Item 9 Labs Corp. for each share of OCG Inc. Upon closing, OCG Inc. will become a wholly-owned direct subsidiary of Item 9 Labs Corp. Upon closing of the transaction, OCG Inc. may nominate, and Item 9 Labs Corp. agrees to appoint, two persons designated by OCG Inc. to Item 9 Labs Corp.’s Board of Directors. The transaction is subject to the adoption of the agreement by the requisite vote of the stockholders of OCG Inc. and Item 9 Labs Corp., approval of the issuance of shares of Item 9 Labs Corp. as merger consideration, an appropriate level and Director and Officers Liability Insurance being in place, financing contingency that Item 9 Labs Corp. must raise approximately $2 million and delivery by OCG Inc. of copies of a lock up and leak out agreement. The Board of Directors of Item 9 Labs Corp. has approved the agreement and the transactions contemplated hereby. The transaction is expected to closing in early July 2020. The transaction is expected to close near the Item 9 Labs’s fiscal year end of September 30, 2020. Michael Weiner and David Mangum of Dorsey & Whitney LLP acted as legal advisors for OCG, Inc. Jessica M. Lockett of Horwitz +Armstrong acted as legal advisor for Item 9 Labs Corp.